Richard Drake to Breast Neoplasms
This is a "connection" page, showing publications Richard Drake has written about Breast Neoplasms.
Connection Strength
1.628
-
Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer. Sci Rep. 2022 Dec 02; 12(1):20801.
Score: 0.414
-
Glycosylation and its implications in breast cancer. Expert Rev Proteomics. 2019 08; 16(8):665-680.
Score: 0.328
-
Challenges to developing proteomic-based breast cancer diagnostics. OMICS. 2011 May; 15(5):251-9.
Score: 0.183
-
Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009 May; 208(5):970-8; discussion 978-80.
Score: 0.160
-
Proteomic approach to breast cancer. Cancer Control. 2007 Oct; 14(4):360-8.
Score: 0.145
-
Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg. 2007 May; 204(5):1065-71; discussion 1071-3.
Score: 0.141
-
Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced N-glycosylation Abundance and Branching. Cancer Res. 2021 05 15; 81(10):2625-2635.
Score: 0.092
-
Core-Fucosylated Tetra-Antennary N-Glycan Containing A Single N-Acetyllactosamine Branch Is Associated with Poor Survival Outcome in Breast Cancer. Int J Mol Sci. 2019 May 23; 20(10).
Score: 0.081
-
Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol. 2004 Oct; 11(10):907-14.
Score: 0.029
-
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. 2004 May 01; 100(9):1814-22.
Score: 0.029
-
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers. 2003-2004; 19(4-5):229-38.
Score: 0.026